Merck KGaA (OTCMKTS:MKKGY) Posts Earnings Results, Misses Expectations By $0.19 EPS

Merck KGaA (OTCMKTS:MKKGY) issued its earnings results on Thursday. The company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.19), Zacks reports. The business had revenue of $6.11 billion for the quarter, compared to analysts’ expectations of $6.20 billion. Merck KGaA had a return on equity of 10.07% and a net margin of 13.92%.

Merck KGaA Stock Performance

MKKGY traded down $0.73 on Friday, reaching $25.76. The stock had a trading volume of 174,695 shares, compared to its average volume of 75,598. The business’s 50-day moving average price is $29.64 and its two-hundred day moving average price is $27.62. The company has a market cap of $16.65 billion, a P/E ratio of 10.26, a price-to-earnings-growth ratio of 5.82 and a beta of 0.96. Merck KGaA has a 12-month low of $24.32 and a 12-month high of $31.00. The company has a current ratio of 1.49, a quick ratio of 0.97 and a debt-to-equity ratio of 0.36.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft downgraded Merck KGaA from a “buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Three analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold”.

About Merck KGaA

Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.

Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.